Literature DB >> 2827913

Direct myocardial and coronary effects of enalaprilat in patients with dilated cardiomyopathy: assessment by a bilateral intracoronary infusion technique.

J M Foult1, O Tavolaro, I Antony, A Nitenberg.   

Abstract

Angiotensin II elicits contractile responses in the coronary arteries and myocardial tissue, which suggests that blockade of the renin-angiotensin system by specific agents should lead to both coronary vasodilation and an alteration of left ventricular inotropism. The present work was designed to delineate--independently from its systemic effects--the intrinsic actions of an angiotensin converting-enzyme inhibitor on the coronary circulation and left ventricular function. To minimize peripheral effects, a bilateral intracoronary infusion of enalaprilat (0.05 mg.min-1, 1 ml.min-1 in each coronary artery) was performed in 16 patients with dilated cardiomyopathy. All patients had normal coronary arteriograms. In 12 patients (group I) the intracoronary infusion of enalaprilat resulted in minimal peripheral changes, with a 5% reduction in the mean aortic pressure (p less than .05) and no significant alteration in indexes of preload, i.e., left ventricular end-diastolic pressure and volume, or of afterload, i.e., left ventricular end-systolic stress and systemic resistances. Myocardial oxygen consumption was also unaffected by the intracoronary infusion of enalaprilat. Coronary vasodilation was demonstrated by a significant elevation of coronary sinus blood flow (+19%, from 181 +/- 73 to 214 +/- 79 ml.min-1, p less than .001) and a reduction of coronary resistance (-18%, from 0.51 +/- 0.17 to 0.41 +/- 0.15 mm Hg.ml-1.min, p less than .001), with a parallel increase in coronary sinus oxygen content and pressure (both p less than .05). Oxygen extraction by the myocardium was reduced (p less than .01).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2827913     DOI: 10.1161/01.cir.77.2.337

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  21 in total

Review 1.  Newer ACE inhibitors. A look at the future.

Authors:  A Salvetti
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

Review 2.  The renin-angiotensin-aldosterone system and cardiac ischaemia.

Authors:  H Ikram
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

Review 3.  Inhibitors of the renin-angiotensin system in established cardiac failure.

Authors:  K Chatterjee
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

4.  The renin-angiotensin system and the heart: a historical review.

Authors:  S J Cleland; J L Reid
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

5.  Why inotropes continue to disappoint in heart failure.

Authors:  P Wilmshurst
Journal:  Br Heart J       Date:  1993-07

6.  Increased angiotensin-I converting enzyme gene expression in the failing human heart. Quantification by competitive RNA polymerase chain reaction.

Authors:  R Studer; H Reinecke; B Müller; J Holtz; H Just; H Drexler
Journal:  J Clin Invest       Date:  1994-07       Impact factor: 14.808

7.  Assessment of the role of the renin-angiotensin system in cardiac contractility utilizing the renin inhibitor remikiren.

Authors:  J P van Kats; L M Sassen; A H Danser; M P Polak; L K Soei; F H Derkx; M A Schalekamp; P D Verdouw
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

8.  Hemodynamic response of a canine model of chronic heart failure to intravenous dobutamine, nitroprusside, enalaprilat, and digoxin.

Authors:  H N Sabbah; T B Levine; M Gheorghiade; T Kono; S Goldstein
Journal:  Cardiovasc Drugs Ther       Date:  1993-06       Impact factor: 3.727

Review 9.  Pharmacokinetic drug interactions with ACE inhibitors.

Authors:  H Shionoiri
Journal:  Clin Pharmacokinet       Date:  1993-07       Impact factor: 6.447

Review 10.  Regional myocardial blood flow and coronary reserve in hypertensive patients. The effect of therapy.

Authors:  O Parodi; D Neglia; G Sambuceti; C Marabotti; C Palombo; L Donato
Journal:  Drugs       Date:  1992       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.